Program
Dual-target CAR-NK cells
Its studies are mostly in Glioblastoma · Carcinoma, Non-Small-Cell Lung · Triple Negative Breast Neoplasms, led by Beijing Biotech.
Furthest: phase 2, since Feb 14, 20265 company-led studies, 5 open or runningNext primary completion: Feb 14, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Beijing Biotech | 55 open or running | phase 2since Feb 14, 2026 | Feb 14, 2026 | Feb 14, 2027phase 2 · NCT07467863 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 14, 2026First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT07467863 · 48 planned · China
- Mar 14, 2026Phase 1 study in GlioblastomaNCT07480941 · 36 planned · China
- Mar 20, 2026Phase 2 study in Breast NeoplasmsNCT07510802 · 60 planned · China
- Apr 18, 2026Phase 1 study in GliomaNCT07551336 · 36 planned · China
- Jun 6, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07641023 · 60 planned · China
Ahead
- Feb 14, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07467863
- Feb 18, 2027Primary completion: phase 1 study in GlioblastomaNCT07480941
- Mar 14, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07641023
- Mar 14, 2027Primary completion: phase 2 study in Breast NeoplasmsNCT07510802
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07641023Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Mar 14, 2027 | 60 |
| NCT07551336Glioma · China | 1 | Recruiting | Apr 14, 2027 | 36 |
| NCT07510802Breast Neoplasms · China | 2 | Recruiting | Mar 14, 2027 | 60 |
| NCT07480941Glioblastoma · China | 1 | Recruiting | Feb 18, 2027 | 36 |
| NCT07467863Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Feb 14, 2027 | 48 |
How it is read
Names in the registry
- “Dual-target CAR-NK cells”, 5 entries
Conditions, from the studies’ own filings
- Glioblastoma, 2 studies
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Triple Negative Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.